Literature DB >> 9406822

Sorting and secretion of a melanosome membrane protein, gp75/TRP1.

Y Xu1, V Setaluri, Y Takechi, A N Houghton.   

Abstract

The melanosome is an organelle specialized for melanin synthesis that is derived from the endocytic pathway. Several melanosome membrane proteins have been identified, forming a family of proteins known as tyrosinase-related proteins. Two members of this family, tyrosinase and gp75, are well-characterized melanocyte differentiation antigens. Our previous studies have shown that gp75, the mouse brown locus protein, is sorted to melanosomes along the endocytic pathway, directed by a hexapeptide sorting signal located in the cytoplasmic tail. In this study, we report the unexpected finding that a portion of gp75 is secreted. Substantial levels of secretory gp75 were detected in melanocytic cells. Cell surface expression of gp75 was also detected, representing 2% of cellular gp75. Characterization of secretory gp75 cells showed that it is: (i) a truncated form that lacks the transmembrane region, the cytoplasmic tail where the endosomal sorting signal is located, and a small portion of the lumenal domain; (ii) more extensively glycosylated than endocytic/melanosomal gp75, containing trans-Golgi processed sugar residues; and (iii) generated post-translationally in an acid sensitive compartment after processing in the trans-Golgi, and secreted rapidly after generation. Thus, these endocytic/melanosomal membrane proteins can be processed to abundant secretory forms, probably in an endocytic compartment through a potentially novel secretory pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406822     DOI: 10.1111/1523-1747.ep12340971

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

1.  Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.

Authors:  Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

2.  High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.

Authors:  Andrew G Brandmaier; Wolfgang W Leitner; Sung P Ha; John Sidney; Nicholas P Restifo; Christopher E Touloukian
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

3.  Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy.

Authors:  Dafeng Chu; Qi Zhao; Jian Yu; Faya Zhang; Hui Zhang; Zhenjia Wang
Journal:  Adv Healthc Mater       Date:  2016-03-17       Impact factor: 9.933

Review 4.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

Authors:  W W Overwijk; N P Restifo
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

5.  Tumor immunity and autoimmunity induced by immunization with homologous DNA.

Authors:  L W Weber; W B Bowne; J D Wolchok; R Srinivasan; J Qin; Y Moroi; R Clynes; P Song; J J Lewis; A N Houghton
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

6.  Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.

Authors:  Sung P Ha; Nicholas D Klemen; Garrett H Kinnebrew; Andrew G Brandmaier; Jon Marsh; Giao Hangoc; Douglas C Palmer; Nicholas P Restifo; Kenneth Cornetta; Hal E Broxmeyer; Christopher E Touloukian
Journal:  J Clin Invest       Date:  2010-11-15       Impact factor: 14.808

Review 7.  Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma.

Authors:  Ghanem Ghanem; Journé Fabrice
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

8.  ESCRT-I function is required for Tyrp1 transport from early endosomes to the melanosome limiting membrane.

Authors:  Steven T Truschel; Sabrina Simoes; Subba Rao Gangi Setty; Dawn C Harper; Danièle Tenza; Penelope C Thomas; Kathryn E Herman; Sara D Sackett; David C Cowan; Alexander C Theos; Graça Raposo; Michael S Marks
Journal:  Traffic       Date:  2009-06-09       Impact factor: 6.215

9.  Immune rejection of mouse tumors expressing mutated self.

Authors:  Fei Duan; Yun Lin; Cailian Liu; Manuel E Engelhorn; Adam D Cohen; Michael Curran; Shimon Sakaguchi; Taha Merghoub; Stephanie Terzulli; Jedd D Wolchok; Alan N Houghton
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection.

Authors:  Kevin D Pavelko; Michael J Hansen; Larry R Pease
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.